SALT LAKE CITY, Oct. 5, 2021 /PRNewswire/ -- Lipocine Inc.
(NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused
on metabolic and endocrine disorders, today announced that the
Company will present at the H.C. Wainwright 5th
Annual NASH Investor Conference being held virtually on
October 12, 2021.
H.C. Wainwright 5th Annual NASH Investor
Conference, October 12, 2021
Presentation time: 3:30 pm ET
A webcast of Lipocine's presentation will be available on
Lipocine's website under "Events & Presentations" in the
Investors section or using the webcast link above. The
webcast will be available on the Lipocine's website for 90
Lipocine Inc. is a clinical-stage
biopharmaceutical company focused on metabolic and endocrine
disorders using its proprietary drug delivery technologies.
Lipocine's clinical development pipeline includes: TLANDO, LPCN
1144, TLANDO XR, LPCN 1148, LPCN 1107 and LPCN 1154. TLANDO, a
novel oral prodrug of testosterone containing testosterone
undecanoate, has received tentative approval from the FDA for
conditions associated with a deficiency of endogenous testosterone,
also known as hypogonadism, in adult males. LPCN 1144, an oral
prodrug of bioidentical testosterone, recently completed a Phase 2
clinical study demonstrating the potential utility in the treatment
of non-cirrhotic NASH. TLANDO XR, a novel oral prodrug
of testosterone, originated and is being developed by Lipocine as a
next-generation oral testosterone product with potential for
once-daily dosing. In a phase 2 clinical evaluation when
administered as once daily or twice daily TLANDO XR met the typical
primary and secondary end points. LPCN 1148 is an oral prodrug of
bioidentical testosterone targeted for the treatment of cirrhosis.
LPCN 1154 is an oral neuro-steroid targeted for the treatment of
post-partum depression. LPCN 1107 is potentially the first
oral hydroxyprogesterone caproate product candidate indicated for
the prevention of recurrent preterm birth and has been granted
orphan drug designation by the FDA. For more information, please
View original content to download
SOURCE Lipocine Inc.